BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28888827)

  • 1. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):699-708. PubMed ID: 37871833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy.
    Song YS; Paeng JC; Kim HC; Chung JW; Cheon GJ; Chung JK; Lee DS; Kang KW
    Medicine (Baltimore); 2015 Jun; 94(23):e945. PubMed ID: 26061323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Yttrium-90 Resin Microsphere Radioembolization: A Retrospective Analysis Using Technetium-99m Macroaggregated Albumin SPECT/CT and Planning Software.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Duncan DP; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):689-698.e3. PubMed ID: 38246416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.
    Elschot M; Nijsen JF; Lam MG; Smits ML; Prince JF; Viergever MA; van den Bosch MA; Zonnenberg BA; de Jong HW
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1965-75. PubMed ID: 24819055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
    Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing
    Noipinit N; Sukprakun C; Siricharoen P; Khamwan K
    Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High quality imaging and dosimetry for yttrium-90 (
    Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Carcinoma Tumor Dose Response After
    Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.